International Journal of Clinical Case Reports 2024, Vol.14, No.3, 117-129 http://medscipublisher.com/index.php/ijccr 127 Liang Y., Huang L., and Liu T., 2021, Development and delivery systems of mRNA vaccines, Frontiers in Bioengineering and Biotechnology, 9: 718753. https://doi.org/10.3389/fbioe.2021.718753 PMid:34386486 PMCid:PMC8354200 Ma F., Yang J., Kang G., Sun Q., Lu P., Zhao Y., Wang Z., Luo J., and Wang Z., 2016, Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study, Clin Microbiol Infect., 22(9): 811.e9-811.e15. https://doi.org/10.1016/j.cmi.2016.06.004 PMid:27345175 Maruggi G., Zhang C., Li J., Ulmer J., and Yu D., 2019, mRNA as a transformative technology for vaccine development to control infectious diseases., Molecular therapy : the journal of the American Society of Gene Therapy, 27(4): 757-772. https://doi.org/10.1016/j.ymthe.2019.01.020 PMid:30803823 PMCid:PMC6453507 Naranbhai V., García-Beltrán W., Chang C., Mairena C., Thierauf J., Kirkpatrick G., Onozato M., Cheng J., Denis K., Lam E., Kaseke C., Tano-Menka R., Yang D., Pavlovic M., Yang W., Kui A., Miller T., Astudillo M., Cahill J., Dighe A., Gregory D., Poznansky M., Gaiha G., Balazs A., and Iafrate A., 2021, Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines, The Journal of Infectious Diseases, 225: 1141-1150. https://doi.org/10.1093/infdis/jiab593 PMid:34888672 PMCid:PMC8689763 Olson S., Newhams M., Halasa N., Price A., Boom J., Sahni L., Irby K., Walker T., Schwartz S., Pannaraj P., Maddux A., Bradford T., Nofziger R., Boutselis B., Cullimore M., Mack E., Schuster J., Gertz S., Cvijanovich N., Kong M., Cameron M., Staat M., Levy E., Chatani B., Chiotos K., Zambrano L., Campbell A., Patel M., and Randolph A., 2021, Effectiveness of pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years-united states, june-september 2021., MMWR, Morbidity and mortality weekly report, 70(42): 1483-1488. https://doi.org/10.15585/mmwr.mm7042e1 PMid:34673751 PMCid:PMC9361838 Pardi N., Hogan M., Porter F., and Weissman D., 2018, mRNA vaccines - a new era in vaccinology, Nature Reviews Drug Discovery, 17: 261-279. https://doi.org/10.1038/nrd.2017.243 PMid:29326426 PMCid:PMC5906799 Pardi N., Hogan M., and Weissman D., 2020, Recent advances in mRNA vaccine technology, Current opinion in immunology, 65: 14-20. https://doi.org/10.1016/j.coi.2020.01.008 Polack F., Thomas S., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J., Marc G., Moreira E., Zerbini C., Bailey R., Swanson K., Roychoudhury S., Koury K., Li P., Kalina W., Cooper D., Frenck R., Hammitt L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D., Mather S., Dormitzer P., Şahin U., Jansen K., and Gruber W., 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, The New England Journal of Medicine, 383: 2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMid:33301246 PMCid:PMC7745181 Rosa S., Prazeres D., Azevedo A., and Marques M., 2021, mRNA vaccines manufacturing: challenges and bottlenecks, Vaccine, 39: 2190-2200. https://doi.org/10.1016/j.vaccine.2021.03.038 PMid:33771389 PMCid:PMC7987532 Sahly H., Baden L., Essink B., Doblecki-Lewis S., Martin J., Anderson E., Campbell T., Clark J., Jackson L., Fichtenbaum C., Zervos M., Rankin B., Eder F., Feldman G., Kennelly C., Han-Conrad L., Levin M., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Polakowski L., Mascola J., Ledgerwood J., Graham B., August A., Clouting H., Deng W., Han S., Leav B., Manzo D., Pajon R., Schödel F., Tomassini J., Zhou H., and Miller J., 2021, Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase, The New England Journal of Medicine, 385: 1774-1785. https://doi.org/10.1056/NEJMoa2113017 Self W., Tenforde M., Rhoads J., Gaglani M., Ginde A., Douin D., Olson S., Talbot H., Casey J., Mohr N., Zepeski A., McNeal T., Ghamande S., Gibbs K., Files D., Hager D., Shehu A., Prekker M., Erickson H., Gong M., Mohamed A., Henning D., Steingrub J., Peltan I., Brown S., Martin E., Monto A., Khan A., Hough C., Busse L., Lohuis C., Duggal A., Wilson J., Gordon A., Qadir N., Chang S., Mallow C., Rivas C., Babcock H., Kwon J., Exline M., Halasa N., Chappell J., Lauring A., Grijalva C., Rice T., Jones I., Stubblefield W., Baughman A., Womack K., Lindsell C., Hart K., Zhu Y., Mills L., Lester S., Stumpf M., Naioti E., Kobayashi M., Verani J., Thornburg N., Patel M., Calhoun N., Murthy K., Herrick J., McKillop A., Hoffman E., Zayed M., Smith M., Seattle N., Ettlinger J., Priest E., Thomas J., Arroliga A., Beeram M., Kindle R., Kozikowski L., Souza L., Ouellette S., Thornton-Thompson S., Mehkri O., Ashok K., Gole S., King A., Poynter B., Stanley N., Hendrickson A., Maruggi E., Scharber T., Jorgensen J., Bowers R., King J., Aston V., Armbruster B., Rothman R., Nair R., Chen J., Karow S., Robart E., Maldonado P., Khan M., So P., Levitt J., Perez C., Visweswaran A., Roque J., Rivera A., Angeles L., Frankel T., Goff J., Huynh D., Howell M., Friedel J., Tozier M., Driver C., Carricato M., Foster A., Nassar P., Stout L., Sibenaller Z., Walter A., Marés J., Olson L., Clinansmith B., Rivas C., Gershengorn H., McSpadden E., Truscon R., Kaniclides A., Thomas L., Bielak R., Valvano W., Fong R., Fitzsimmons W., Blair C., Valesano A., Gilbert J., Crider C., Steinbock K., Paulson T., Anderson L., Kampe C., Johnson J., Mchenry R., Blair M., Conway D., LaRose M., Landreth L., Hicks M., Parks L., Bongu J., Mcdonald D., Cass C., Seiler S., Park D., Hink T., Wallace M., Burnham C., and Arter O., 2021, Comparative effectiveness of moderna, pfizer-bionTech, and janssen (johnson & johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - united states, march-august 2021, Morbidity and Mortality Weekly Report, 70: 1337-1343. https://doi.org/10.15585/mmwr.mm7038e1 PMid:34555004 PMCid:PMC8459899
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==